Pharmaceutical company Mylan NV (Nasdaq:MYL) (TASE:MYL) disclosed on Monday the launch of a sub-license agreement to expand access to chronic hepatitis C medicines in developing countries in partnership with the Medicines Patent Pool (MPP).
Under the terms of the agreement, Mylan is granted the license to produce and market a generic version of Bristol-Myers Squibb's DAKLINZA (daclatasvir) Tablets, 30 mg and 60 mg, for distribution in 112 low and middle income countries.
According to the company, Daclatasvir Tablets, 30 mg and 60 mg, are indicated for use with sofosbuvir, with or without ribavirin, for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection in the US and genotype 1, 3 and 4 in Europe.
This license agreement enables Mylan to develop fixed-dose combinations of Daclatasvir Tablets that offer the potential to treat all of the six major genotypes of HCV.
Earlier in 2016, the WHO added several new hepatitis C treatments, including daclatasvir, to its essential medicines list, highlighting the urgent need to promote equitable access to innovative medicines. Globally, 130m to 150m people have chronic hepatitis C infection2 and the vast majority live in low and middle income countries.
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva